Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

3.3K
Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
3.3K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.7K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.7K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.5K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.5K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.7K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.7K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

782
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
782

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to Improve Patient Adherence During Helicobacter pylori Diagnosis and Treatment.

Helicobacter·2026
Same author

Helicobacter 30 Years On: A Message From the Editor, Emeritus.

Helicobacter·2026
Same author

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.

Gastroenterology·2026
Same author

40 years after the discovery of <i>Helicobacter Pylori</i>: Performing optimized "subtraction" for clinical eradication.

iMetaOmics·2026
Same author

Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population.

Helicobacter·2025
Same author

Elastic Cytomatrix Dynamics Influences Metabolic Rate and Tumor Microenvironment Formation.

Cancers·2025
Same journal

Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.

World journal of gastroenterology·2026
Same journal

Small animal <i>ex vivo</i> machine perfusion of the liver: A comprehensive literature review.

World journal of gastroenterology·2026
Same journal

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars.

World journal of gastroenterology·2026
Same journal

Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.

World journal of gastroenterology·2026
Same journal

Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique.

World journal of gastroenterology·2026
Same journal

Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> peroxisome proliferator-activated receptor alpha pathway activation.

World journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Mouse Models Of Helicobacter Infection And Gastric Pathologies
07:43

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

23.2K

Autoimmune gastritis: Pathologist's viewpoint.

Irene Coati1, Matteo Fassan1, Fabio Farinati1

  • 1Irene Coati, Matteo Fassan, Massimo Rugge, Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, 35121 Padua, Italy.

World Journal of Gastroenterology
|November 18, 2015
PubMed
Summary
This summary is machine-generated.

Autoimmune gastritis, targeting parietal cells, is rising as Helicobacter pylori infections decline. Standardized histology and multidisciplinary approaches are needed for early detection of gastric neoplasms.

Keywords:
Autoimmune gastritisCarcinoidsMetaplasiaOperative link for gastritis assessment staging

More Related Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.7K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

Related Experiment Videos

Last Updated: Mar 30, 2026

Mouse Models Of Helicobacter Infection And Gastric Pathologies
07:43

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

23.2K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.7K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

Area of Science:

  • Gastroenterology
  • Immunology
  • Oncology

Background:

  • Western countries observe a decrease in Helicobacter pylori-associated gastritis.
  • Autoimmune gastritis, targeting parietal cells, shows increasing epidemiological and clinical significance.
  • This condition involves auto-antibodies and T cells against parietal cell proton pump and intrinsic factor, primarily affecting the gastric corpus-fundus.

Purpose of the Study:

  • To highlight the shift in gastritis prevalence from H. pylori to autoimmune causes.
  • To underscore the risk of gastric neoplasms (neuroendocrine tumors, adenocarcinomas) in advanced autoimmune gastritis.
  • To emphasize the need for reliable biomarkers and standardized diagnostic approaches for secondary prevention.

Main Methods:

  • Review of epidemiological trends in gastritis.
  • Analysis of the pathophysiology of autoimmune gastritis and its link to gastric cancer.
  • Discussion on current diagnostic limitations and future directions for standardization.

Main Results:

  • Autoimmune gastritis is becoming more prevalent, particularly in Western nations.
  • Advanced autoimmune gastritis leads to atrophic and metaplastic changes, creating a risk for gastric neoplasms.
  • Currently, no reliable biomarkers exist to identify high-risk patients for gastric cancer development.

Conclusions:

  • Standardizing autoimmune gastritis histology and classification is crucial.
  • Multidisciplinary diagnostic strategies integrating endoscopy, serology, histology, and molecular profiling are essential for secondary prevention.
  • Further research is needed to develop biomarkers for early risk identification in autoimmune gastritis.